J.P. Morgan Roundtable: Biotech's Reputation Tarnished By Drug Pricing Concerns
This article was originally published in Scrip
Executive Summary
Big pharma companies are used to being criticized for high drug prices, but biotechnology companies that don't even have a product on the market also feel vilified, perhaps for the first time, over the cost of prescription medicines.